160 likes | 248 Views
MRS Entrepreneurship Challenge. Team 14. Disclosure.
E N D
MRS Entrepreneurship Challenge Team 14 Disclosure NanoMed recognizes that the intellectual property as proposed to carry out the ideation concepts outlined in this presentation is owned by the Ohio State University (OSU) (background and any unprotected potential intellectual property conceived and or reduced to practice in the generation of this business assessment and plan). NanoMed is not yet a legal entity but acknowledges that, as a legal entity, it may require a license from OSU to carry out all or part of the concepts outlined in this presentation. Discussions with OSU are in progress. MRS Entrepreneurship Challenge
MRS Entrepreneurship Challenge Team 14 ZipDiscGene Delivery System
Researchers successfully transformed adult skin cells into stem cells, removing ethical barriers “researchers use more than one method of gene delivery” – Biocompare Surveys and Reports (2007) ZipDiscTM Propelling research to faster cures
MRS Entrepreneurship Challenge PRIMARY MARKET: Genetic Research Labs Life Science Tools & Services • Total market size $40.5 billion Gene Delivery Products • Direct competition $1.2 billion SECONDARY MARKETS Stem Cell Products • Projected to experience 50% growth over 10 yrs • $10 billion by 2016 Pharmaceuticals • Total market size $467 billion Agriculture Biotechnology • Total market size $53.9 billion
MRS Entrepreneurship Challenge ZipDiscGene Delivery System The ZipDisc custom applicator and voltage source One-time use ZipDisc disposable cartridges Product Line • Release incremental innovations to initial product • Broaden applications and increase throughput • Follow-on products Competitive Advantages • 90% success rate • 95% cell survival rate • Non-viral delivery method • User-friendly
MRS Entrepreneurship Challenge CUSTOMER “...make the lab bigger, better, faster and enable more discoveries.” – Dr. Brian Kaspar, Nationwide Children's Hospital “The retrovirus can be a Trojan horse that can carry all sorts of problems” – Dr. Douglas Melton, Harvard Stem Cell Institute “The limitations of current delivery technologies ... are substantial barriers to the development and growth of the overall RNAi market” –Frost & Sullivan, “U.S. RNAi Markets,” 2006
MRS Entrepreneurship Challenge VALUE PROPOSITION ZipDisc increases success rate of gene transfer from 15-70% to 90% ZipDisc increases cell survival rate from 50% to 95% ZipDisc utilizes a disposable cartridge with no viral agents ZipDisc injects similar numbers of cells at comparable cost to competitors Faster Research + Higher Success Rates = More Cures
MRS Entrepreneurship Challenge TECHNOLOGY PET array of nanoscale nozzles Nozzle array cells IP Position • International patent application filed; moving to patent in U.S. & Europe • Patent application includes core technology & numerous applications • Ongoing discussions with OSU technology licensing office Stage of Development • Prototype of entire delivery system • Entering independent testing phase • High stage of development with little science risk
PRE-COMMERCIALIZATION MARKET ENTRY GROWTH & EXPANSION 6 Months 2 Years 5 Years Timeline Secure license Complete beta testing Secure seed capital Form company Apply for grants Secure 3-5 key pilot users Raise B round funding Build management team Secure Mfg and Distribution Partners Market and distribute to industry leaders Full-scale market penetration Scale up production Introduce follow-on products Prepare to exit $400 K $600 K $1.0 M DEVELOPMENT PLAN Capital Funding Needed
MRS Entrepreneurship Challenge DISTRIBUTION PLAN Key Partners • Distribution Cardinal Health of Ohio or other leading Medical Supply Chain Service company • Production Zyvex Performance Materials or other leading edge manufacturer of nanomaterial devices • Testing The Solove Research Institute at the James Cancer Hospital • Business Model • Razor and disposable blade model: • Sell ZipDisc custom applicator at competitive price • Generate continuous revenue stream from ZipDisc disposable cartridges • Sales Model • Establish a base of pilot users through direct sales • Attract distribution partner to quickly ramp up sales
MRS Entrepreneurship Challenge A STRONG TEAM & BOARD Business Team Paul Dymerski, PhD Interim CEO Founder of multiple technology startups Seth Cramer Interim CFO MBA with experience in multiple startups Bruce Caldwell Operations MBA Candidate & 20 yr. R&D Manager Mihaela Jekic, MS Technology PhD Candidate in Biomedical Engineering Eric Cochran, MS Marketing PhD Candidate in Physics/Medical Devices Aaron Sander Sales PhD Candidate in Physics Advisory Board James Lee, PhD NSF Director for Ohio Polymer & Composite Engineering Sharell Mikesell, PhD Executive Director of the Ohio Polymer Strategy Council Tom Zupancic, PhD 25 years in gene research and transfection industry John Bair Founder, Pinnacle Data Systems Andy Dickson Director, Ohio Tech Angel Fund
MRS Entrepreneurship Challenge COMPETITION MANUFACTURERS WHOLESALERS CUSTOMERS Bio-Rad Fisher Thermo Invitrogen GE Healthcare Qiagen IBI-Shelton Stratagene Research OSU… Pharmaceutical Eli-Lilly… Biotech Monsanto… Cancer Hospitals Johns-Hopkins… Bio-Rad Fisher Thermo Invitrogen GE Healthcare McKesson Amersourcebergen Beckman-Coulter Cardinal Health
MRS Entrepreneurship Challenge COMPETITIVE ADVANTAGE Electroporation (Bio-Rad Laboratories) • Very low cell survival (<20%) • Very low success rate (<40%) • ZipDisc provides significant advantage through high success rate (90%) & survival rate (95%) Viral Vectors (Stratagene) • Long prep time (1-3 months) • Health risk • ZipDisc provides significant advantage through time efficiency (30 min), versatility, and elimination of health risks Lipofection (Invitrogen) • Low success rate (<70%) • Cell toxicity • ZipDisc provides significant advantage through high success rate (90%)
PROFORMA INCOME STATEMENT Capital Required: $2MM High Margin Growing Market Low Upfront Investment MRS Entrepreneurship Challenge
MRS Entrepreneurship Challenge EXIT STRATEGY • Valuation • March 2006, Applied Biosystems acquires Ambion for $273 million • At the time, Ambion posted $52 million annual revenue • Acquisition after year 5 • Established profitable enterprise • Demonstrated effectiveness across numerous gene & drug platforms • Developed robust product line • Established product as the standard for stem cell research • Achieved high level of brand recognition Alternative Strategy • IPO, if current predictions of market share are overly conservative
Success Rate of Gene Transfer ZipDisc Gene Delivery System Standard Method